FDA Approves Cosentyx for Pediatric Hidradenitis Suppurativa
Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of pediatric patients aged 12 years and older with moderate…
Read More...
Read More...
